AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$CATX

Lantheus Alpha Therapy, LLC sold $357K of CATX

Lantheus Alpha Therapy, LLC sold 113,914 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.14 ($3.12–$3.14, $0.36M total) across 2 trades over 2026-08-31 to 2026-09-01.

Original reporting
SEC EDGAR · Lantheus Alpha Therapy, LLC
Published Sep 4, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CATX
Neutral
high confidence
Mentioned
$CATX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CATXNeutralLow
01

Why it matters

The disclosed sale is a routine insider transaction with limited market impact.

02

Market read

Minor relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases could change relevance of insider activity.

Relevance 4/10Novelty 4/10Timing: filed Sep 4 2026

Background

SEC Form 4 filing reports insider transactions for public companies.

Company-level read

Ticker impact

$CATXNeutralHigh confidence
Context

Form 4 disclosed Lantheus Alpha Therapy sold $357K of Perspective Therapeutics shares, reducing its stake to 11.56M shares.

Expected impact

little to no immediate price movement

Evidence & confidence

The transaction size is modest relative to market cap and insider ownership remains high.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional effect.

Global

Limited to Perspective Therapeutics investors.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; watch for further disposals.

Key entities

  • company
    Perspective Therapeutics, Inc.

    Biopharma company whose ticker is CATX.

  • insider
    Lantheus Alpha Therapy, LLC

    10% owner selling shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CATX insider trading history →

Related articles

OCT 8
$CATXMedAI 8/10

Perspective Granted FDA Fast Track for PSV359 in FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics (CATX) received FDA Fast Track designation for PSV359, an investigational FAP-targeted alpha therapy, to treat adult patients with locally advanced or metastatic FAP-positive solitary fibrous tumors. The drug is currently in a Phase 1/2a study, with early human imaging showing promising results. Fast Track designation may expedite development and review processes.

tradingview.com1 min
OCT 8
$CATXMedAI 8/10

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or…

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors SEATTLE, Oct. 08, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Co

SEC EDGAR 8-K2 min
OCT 8
$CATXMedAI 8/10

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics (CATX) received FDA Fast Track Designation for PSV359, a treatment for FAP-positive solitary fibrous tumors. The therapy targets FAP-α, a protein linked to aggressive cancers, with limited current treatment options. The FDA program aims to expedite development and review for serious conditions with unmet medical needs.

globenewswire.com2 min
OCT 7
$CATXLowAI 8/10

Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors

Perspective Therapeutics (NYSE: CATX) will present clinical data on its [212Pb]VMT-α-NET program for advanced neuroendocrine tumors at the NANETS 2026 symposium. The company is developing radiopharmaceutical treatments using alpha-emitting isotopes to target cancer cells. Interim data was previously presented at the 2026 ASCO meeting, with additional data planned for future conferences. The company is also advancing other clinical-stage programs in the U.S.

quiverquant.com1 min